1.2 Agonists and antagonists

Agonists and antagonists are the core ligand types in pharmacodynamics, and understanding how they interact with receptors is essential for predicting drug behavior. This topic covers ligand classification, receptor-ligand binding, dose-response relationships, receptor theory, desensitization, and therapeutic applications.

Types of receptor ligands

Receptor ligands are molecules that bind to receptors and modulate their activity. The type of response (or lack of response) a ligand produces depends on where it binds, how tightly it binds, and what conformational change it induces in the receptor.

Agonists vs antagonists

Agonists bind to a receptor and activate it, triggering a downstream biological response. Antagonists also bind to the receptor but do not activate it. Instead, they block the binding site and prevent agonists from producing their effect.

Both agonists and antagonists typically compete for the same binding site on the receptor, called the orthosteric site.

• Acetylcholine is an endogenous agonist at nicotinic and muscarinic receptors. It activates these receptors as part of normal neurotransmission.
• Naloxone is an antagonist at opioid receptors. It displaces opioids from the receptor without activating it, which is why it reverses opioid overdose.

Partial vs full agonists

Not all agonists produce the same magnitude of response. Full agonists can elicit the maximal biological response the receptor system is capable of producing. Partial agonists activate the receptor but can only produce a submaximal response, even when every receptor is occupied.

This difference comes down to intrinsic efficacy: a partial agonist is less effective at stabilizing the fully active receptor conformation.

• Morphine is a full agonist at mu-opioid receptors, producing strong analgesia.
• Buprenorphine is a partial agonist at the same receptor. It provides pain relief but with a ceiling effect, which also gives it a better safety profile for opioid dependence treatment.

An important clinical nuance: in the presence of a full agonist, a partial agonist can actually act as a functional antagonist by competing for the receptor and reducing the overall response.

Inverse agonists

Some receptors have constitutive activity, meaning they produce a low-level signal even without any ligand bound. Inverse agonists bind to these receptors and reduce that basal activity, effectively producing the opposite effect of an agonist.

This is different from a simple antagonist, which would only block agonist binding without affecting constitutive activity. A neutral antagonist brings the response to baseline; an inverse agonist pushes it below baseline.

• Rimonabant is an inverse agonist at cannabinoid CB1 receptors. It reduces constitutive CB1 signaling rather than simply blocking cannabinoid binding.

Allosteric modulators

Allosteric modulators bind to a site on the receptor that is distinct from the orthosteric site. Because they don't compete directly with the endogenous ligand, they can fine-tune receptor activity rather than switching it fully on or off.

• Positive allosteric modulators (PAMs) enhance the effect of the orthosteric ligand (increase affinity, efficacy, or both).
• Negative allosteric modulators (NAMs) reduce the effect of the orthosteric ligand.

Benzodiazepines are a classic example of PAMs. They bind to an allosteric site on the $\text{GABA}_A$ receptor and increase the receptor's response to GABA, enhancing chloride ion conductance. They don't activate the receptor on their own at therapeutic doses, which contributes to their relative safety compared to direct agonists like barbiturates.

Receptor-ligand interactions

The way a ligand binds to its receptor determines much of its pharmacological profile. Two key properties govern this interaction: how tightly the ligand binds (affinity) and what it does once bound (efficacy).

Binding affinity

Binding affinity describes the strength of the interaction between a ligand and its receptor. A ligand with high affinity binds tightly and dissociates slowly.

Affinity is quantified by the dissociation constant ($K_d$), which represents the ligand concentration at which 50% of receptors are occupied at equilibrium. A lower $K_d$ means higher affinity. For example, a drug with a $K_d$ of 1 nM binds much more tightly than one with a $K_d$ of 100 nM.

Affinity is determined by the complementarity between the ligand's chemical structure and the receptor's binding pocket, involving hydrogen bonds, ionic interactions, van der Waals forces, and hydrophobic interactions.

Efficacy of agonists

Efficacy (also called intrinsic efficacy) refers to the ability of an agonist to activate the receptor and produce a biological response once it's bound. Affinity gets the ligand to the receptor; efficacy determines what happens next.

• Full agonists have high efficacy and can produce the maximal system response.
• Partial agonists have lower efficacy and produce a submaximal response regardless of concentration.
• Antagonists have affinity but zero efficacy.

Efficacy depends on how well the ligand stabilizes the active conformation of the receptor and how efficiently that conformation couples to downstream signaling.

Competitive vs non-competitive antagonism

Competitive antagonists bind to the orthosteric site and directly compete with the agonist for receptor occupancy. Their effect is surmountable: if you increase the agonist concentration enough, the agonist will outcompete the antagonist. On a dose-response curve, competitive antagonism causes a rightward shift without reducing the maximal response.

Non-competitive antagonists bind to an allosteric site (or sometimes irreversibly to the orthosteric site) and reduce the maximal response the agonist can achieve. Increasing the agonist concentration cannot fully overcome this blockade. On a dose-response curve, non-competitive antagonism depresses the maximum of the curve.

Reversible vs irreversible binding

Most drug-receptor interactions are reversible, relying on non-covalent forces. The ligand eventually dissociates, and the receptor returns to its unoccupied state.

Irreversible binding involves formation of a covalent bond between the ligand and the receptor. This effectively removes that receptor from the available pool until the cell synthesizes new receptors. The effects are long-lasting and persist well after the drug is cleared from plasma.

• Phenoxybenzamine is an irreversible antagonist at alpha-adrenergic receptors. It's used before surgery for pheochromocytoma because its sustained blockade prevents dangerous catecholamine surges.

Dose-response relationships

Dose-response curves are the primary tool for quantifying drug action. They show how the magnitude of a biological effect changes as drug concentration increases, and they allow you to compare drugs in terms of potency and efficacy.

Graded vs quantal dose-response curves

Graded dose-response curves plot the response of a single biological system (a tissue, a cell population) against increasing drug concentration. The response increases continuously from zero to maximum. These curves are used to determine potency and maximal efficacy of individual drugs.

Quantal dose-response curves plot the percentage of a population that shows a defined all-or-nothing response (e.g., seizure, death, therapeutic effect) at each dose. These curves are used to determine population-level parameters:

• $ED_{50}$: the dose at which 50% of the population shows the therapeutic effect
• $LD_{50}$: the dose at which 50% of the population dies (determined in animal studies)
• $TD_{50}$: the dose at which 50% of the population shows a toxic effect

Potency vs efficacy

These two terms are frequently confused, but they describe different things.

Potency is about the dose required. A more potent drug achieves a given effect at a lower concentration. On a graded dose-response curve, a more potent drug's curve sits further to the left.

Efficacy is about the maximum effect achievable. A drug with higher efficacy produces a greater maximal response, regardless of the dose needed to get there.

EC50 and IC50 values

• $EC_{50}$ (half maximal effective concentration) is the agonist concentration that produces 50% of its maximum response. Lower $EC_{50}$ = higher potency.
• $IC_{50}$ (half maximal inhibitory concentration) is the antagonist concentration that reduces the agonist response by 50%. Lower $IC_{50}$ = more potent inhibition.

These values are used to compare drugs within the same class. For instance, if Drug A has an $EC_{50}$ of 10 nM and Drug B has an $EC_{50}$ of 100 nM for the same receptor, Drug A is 10-fold more potent.

Therapeutic index

The therapeutic index (TI) is the ratio of the toxic dose to the therapeutic dose:

$TI = \frac{TD_{50}}{ED_{50}}$

A higher TI means a wider margin between the effective dose and the toxic dose, indicating a safer drug. For example, a drug with a TI of 100 is much safer to dose than one with a TI of 2.

Drugs with narrow therapeutic indices (e.g., warfarin, lithium, digoxin) require careful dose monitoring because the effective and toxic doses are close together.

Receptor theory

Several theoretical models attempt to explain how ligand-receptor interactions translate into biological responses. Each model captures different aspects of receptor pharmacology.

Occupancy theory

Occupancy theory (Clark, 1933) is the simplest model. It states that the biological response is directly proportional to the fraction of receptors occupied by the ligand. Maximum response occurs when all receptors are occupied.

This model works well as a starting framework, but it has limitations:

• It cannot explain why partial agonists produce a submaximal response even at full receptor occupancy.
• It doesn't account for receptor reserve (spare receptors), where a maximal response can be achieved without occupying every receptor.

Rate theory

Rate theory (Paton, 1961) proposes that the response depends not on how many receptors are occupied at any given moment, but on the rate of ligand-receptor association events. Each binding event generates a quantum of response.

Under this model, agonists with fast on-off kinetics produce greater responses because they generate more association events per unit time. This can help explain differences between full and partial agonists, though the model has largely been superseded by more modern frameworks.

Induced fit model

The induced fit model proposes that the receptor changes its conformation in response to ligand binding. The ligand doesn't simply slot into a pre-existing pocket; instead, the receptor adapts its shape to accommodate the ligand, and this conformational change is what triggers activation.

This model explains why structurally different ligands can activate the same receptor to different degrees: each ligand induces a slightly different conformational change.

Conformational selection model

The conformational selection model (also called the pre-existing equilibrium model) proposes that receptors naturally fluctuate between multiple conformational states, including active and inactive forms. Ligands don't induce a new conformation; they selectively bind to and stabilize a conformation that already exists in the equilibrium.

• Agonists preferentially bind and stabilize the active conformation.
• Inverse agonists preferentially bind and stabilize the inactive conformation.
• Neutral antagonists bind equally to both conformations.

This model elegantly explains constitutive receptor activity (the receptor occasionally adopts the active conformation on its own) and the mechanism of inverse agonists.

Receptor desensitization and regulation

Receptors are not static targets. Cells actively regulate receptor number and responsiveness, which has direct consequences for drug efficacy over time.

Mechanisms of desensitization

Receptor desensitization is the reduction in receptor responsiveness following prolonged or repeated agonist exposure. It occurs through several mechanisms:

1. Phosphorylation: Kinases such as G protein-coupled receptor kinases (GRKs) phosphorylate the activated receptor, reducing its ability to couple to downstream signaling proteins.
2. Uncoupling: Arrestin proteins bind to the phosphorylated receptor and physically block G protein interaction.
3. Internalization: The receptor is removed from the cell surface via endocytosis (see below).

These steps can occur within seconds to minutes of agonist exposure.

Receptor internalization

After desensitization, receptors can be internalized into the cell through clathrin-coated pits. Once inside, the receptor faces one of two fates:

• Recycling: The receptor is dephosphorylated and returned to the cell surface, restoring sensitivity. This is called resensitization.
• Degradation: The receptor is trafficked to lysosomes and broken down, permanently reducing receptor number.

The balance between recycling and degradation determines how quickly a cell recovers its responsiveness.

Up-regulation vs down-regulation

• Down-regulation is a decrease in total receptor number, typically caused by prolonged agonist exposure. It involves increased receptor degradation and decreased receptor synthesis.
• Up-regulation is an increase in receptor number, often occurring during prolonged antagonist exposure or in the absence of the endogenous ligand.

These changes in receptor density alter the cell's sensitivity to ligands. Up-regulation during chronic antagonist use is clinically relevant: if the antagonist is suddenly withdrawn, the increased receptor population can cause a rebound effect with exaggerated agonist responses.

Impact on drug efficacy

Desensitization and down-regulation are the molecular basis of tolerance, where increasing doses of a drug are needed to achieve the same effect.

• Long-term opioid use leads to mu-opioid receptor desensitization and down-regulation, requiring dose escalation for equivalent analgesia.
• Chronic beta-agonist use in asthma can reduce bronchodilator effectiveness over time.

Strategies to manage this include:

• Intermittent dosing (drug holidays) to allow receptor resensitization
• Using partial agonists, which tend to cause less desensitization than full agonists
• Combination therapy to reduce reliance on a single receptor pathway

Agonist and antagonist examples

Different receptor families are targeted by distinct classes of agonists and antagonists. Knowing specific examples and their clinical uses helps connect pharmacodynamic principles to real therapeutics.

G protein-coupled receptor ligands

GPCRs are the largest receptor superfamily and the target of roughly 34% of all FDA-approved drugs.

GPCR agonists:

• Epinephrine (adrenergic receptors): used in anaphylaxis and cardiac arrest
• Histamine (histamine receptors): endogenous mediator of allergic responses
• Serotonin (serotonin receptors): endogenous neurotransmitter involved in mood regulation

GPCR antagonists:

• Propranolol (beta-adrenergic receptors): non-selective beta-blocker used for hypertension and anxiety
• Cimetidine (histamine $H_2$ receptors): reduces gastric acid secretion for peptic ulcer treatment
• Ondansetron ($5\text{-HT}_3$ serotonin receptors): antiemetic used during chemotherapy

Ion channel modulators

Ion channels control the flow of ions across cell membranes and are critical targets for drugs affecting neuronal and cardiac excitability.

Ion channel agonists/modulators:

• Nicotine activates nicotinic acetylcholine receptors (ligand-gated $\text{Na}^+$/$\text{K}^+$ channels)
• Benzodiazepines are PAMs at $\text{GABA}_A$ receptors (ligand-gated $\text{Cl}^-$ channels), enhancing inhibitory neurotransmission

Ion channel antagonists/blockers:

• Memantine blocks NMDA glutamate receptors (used in Alzheimer's disease to reduce excitotoxicity)
• Nifedipine blocks L-type calcium channels (used as an antihypertensive and antianginal)

Nuclear receptor agonists and antagonists

Nuclear receptors are intracellular receptors that function as ligand-activated transcription factors, directly regulating gene expression. Their effects are slower in onset but longer-lasting than those of membrane receptors.

Nuclear receptor agonists:

• Estradiol (estrogen receptors): endogenous hormone; synthetic analogs used in hormone replacement therapy
• Dexamethasone (glucocorticoid receptors): potent anti-inflammatory and immunosuppressant

Nuclear receptor antagonists:

• Tamoxifen (estrogen receptors): selective estrogen receptor modulator (SERM) used in estrogen receptor-positive breast cancer
• Mifepristone (progesterone receptors): used for medical termination of pregnancy

Enzyme activators and inhibitors

While enzymes are not classical receptors, they are important drug targets that follow similar principles of activation and inhibition.

Enzyme activators:

• Riociguat (soluble guanylate cyclase activator): used in pulmonary arterial hypertension
• Cinacalcet (calcium-sensing receptor): a calcimimetic used in hyperparathyroidism (note: this is technically an allosteric modulator of a GPCR, not a classical enzyme activator)

Enzyme inhibitors:

• Sildenafil (phosphodiesterase type 5 inhibitor): prevents breakdown of cGMP, used for erectile dysfunction and pulmonary hypertension
• Captopril (angiotensin-converting enzyme inhibitor): blocks conversion of angiotensin I to angiotensin II, used for hypertension and heart failure

Therapeutic applications

The choice between using an agonist or antagonist depends on whether the therapeutic goal is to enhance or suppress a particular receptor-mediated pathway.

Agonists in disease treatment

Agonists are used when a signaling pathway is underactive or when you need to mimic the effect of an endogenous ligand.

• Parkinson's disease: Dopamine agonists (e.g., pramipexole) or the dopamine precursor levodopa compensate for the loss of dopaminergic neurons in the substantia nigra.
• Type 2 diabetes: GLP-1 receptor agonists (e.g., semaglutide) enhance insulin secretion and suppress glucagon release in a glucose-dependent manner.
• Asthma: $\beta_2$-adrenergic receptor agonists (e.g., salbutamol) relax bronchial smooth muscle to relieve bronchoconstriction.

Antagonists as therapeutic agents

Antagonists are used when a pathway is overactive or when blocking a receptor prevents a pathological process.

• Allergies: Antihistamines (e.g., cetirizine) block $H_1$ histamine receptors, reducing symptoms like itching and rhinorrhea.
• Hypertension: Beta-blockers (e.g., metoprolol) block $\beta_1$-adrenergic receptors in the heart, reducing heart rate and cardiac output.
• Opioid overdose: Naloxone rapidly displaces opioids from mu-opioid receptors, reversing respiratory depression.

Rational drug design strategies

Rational drug design uses knowledge of receptor structure and ligand properties to develop new therapeutics, rather than relying on trial-and-error screening.

1. Structure-based drug design: Uses the 3D crystal structure or cryo-EM structure of the target receptor to design ligands that fit the binding pocket with high complementarity.
2. Ligand-based drug design: Analyzes the structure-activity relationships (SAR) of known active compounds to guide the synthesis of improved analogs.
3. Computational methods: Virtual screening and molecular docking simulate ligand-receptor interactions in silico to prioritize compounds for synthesis and testing.

Challenges in agonist/antagonist development

Developing clinically useful agonists and antagonists involves several recurring challenges:

• Receptor subtype selectivity: Many receptor families have multiple subtypes (e.g., five muscarinic receptor subtypes) with different tissue distributions and functions. Achieving selectivity for one subtype while avoiding others is difficult but critical for minimizing side effects.
• Off-target effects: Drugs may interact with unintended receptors or enzymes, leading to adverse effects. For example, first-generation antihistamines also block muscarinic receptors, causing dry mouth and sedation.
• Interspecies differences: Receptor structure and pharmacology can differ between species, making it challenging to translate preclinical animal data to human efficacy and safety predictions.